
Diabetes (Credit: Canva)
Diabetes insipidus (DI) is a rare medical condition that disrupts the body's ability to regulate water, resulting in excessive thirst and an unusually high volume of urine. This condition affects the kidneys' ability to concentrate urine and causes individuals to produce between 3 and 20 quarts of dilute, colourless urine daily, compared to an average of 1 to 2 quarts. It is pertinent to note that DI is not related to diabetes mellitus, which disrupts the body's insulin production.
This condition results from damage to the hypothalamus or pituitary gland, which impairs the production or release of vasopressin, a hormone responsible for water retention. When vasopressin levels are inadequate, the kidneys fail to conserve water, leading to excessive urination. It can result from Brain injuries or surgeries, tumours, infections or inflammation and aneurysms.
Nephrogenic Diabetes Insipidus
This type occurs when the kidneys fail to respond to vasopressin, causing excessive fluid loss. Common triggers include chronic kidney disease, and electrolyte imbalances, such as high calcium or low potassium levels. Additionally, medications like lithium
and urinary tract blockages can also cause Nephrogenic DI.
A rare condition seen only during pregnancy, this occurs when the placenta produces an enzyme that breaks down vasopressin or increases prostaglandin levels, reducing kidney sensitivity to the hormone. Symptoms of this are usually mild and often resolve postpartum but can recur in future pregnancies.
In severe cases, dehydration may develop, manifesting as fatigue, dizziness, dry mouth, confusion, nausea, or fainting. Infants and children with DI may exhibit crankiness, poor feeding, slow growth, fever, or vomiting.
DI stems from issues with vasopressin production or response. Central DI arises from damage to brain structures, while nephrogenic DI relates to kidney dysfunction. Risk factors include:
- Genetic mutations affecting water regulation
- Certain medications like diuretics or lithium
- Metabolic disorders that alter calcium or potassium levels
- Brain injuries or surgeries
Diagnosis And Testing
Diagnosing DI involves a combination of medical history, physical exams, and specialized tests:
- Urinalysis: Evaluates urine concentration and glucose levels to distinguish DI from diabetes mellitus.
- Blood tests: Check electrolyte, glucose, and vasopressin levels.
- Water deprivation test: Measures changes in weight, blood sodium, and urine concentration during fluid restriction.
- MRI: Detects abnormalities in the hypothalamus or pituitary gland.
- Genetic screening: Identifies inherited risk factors.
Although DI is rare, affecting about 1 in 25,000 people, early diagnosis and targeted treatment can significantly improve quality of life. Researchers continue to explore its causes and treatments to better support those living with this challenging condition.
Credit: AI
Massive wildfires have ravaged several parts of Canada and other regions of the world, filling the air with hazardous smoke. This has triggered health warnings far beyond the fire zones.
While most people experience immediate breathing problems during and after wildfires, experts say that some health effects can persist long after the skies clear.
Wildfire smoke is composed of harmful gases and microscopic particles known as PM2.5. These tiny particles are small enough to travel into our lungs and enter the bloodstream, where they can trigger inflammation throughout the body.
Unlike typical air pollution, wildfire smoke also contains toxic substances released from burning homes, plastics, furniture, vehicles, electronics, and industrial materials, making prolonged exposure particularly harmful.
Also read: Delhi's Poor AQI, Monsoon Conditions Put Children's Lungs at Risk: Ways to Keep Kids Safe
Prolonged exposure to wildfire smoke can have long-term effects on the respiratory system. Possible health effects may include:
Children, older adults, and people with existing lung conditions face the highest risk because their lung function is already compromised.
Also read: Phones, Pollution, AI: What Is Driving Cognitive Decline In Humans?
The tiny particles in wildfire smoke don't just stay confined to the lungs. Once they enter the bloodstream, they can affect the cardiovascular system. In the long run, research says wildfire smoke exposure can lead to:
With frequent incidences of wildfires, scientists are looking into how wildfire smoke affects the brain. Emerging evidence suggests smoke exposure may contribute to:
Wildfires can affect mental health in more than one way. Besides the stress of evacuation and property loss, smoke exposure itself may contribute to mental health problems directly. One is at the risk of the following mental health issues after exposure:
Communities repeatedly exposed to wildfire events may experience prolonged psychological distress that could often go undetected.
Growing evidence suggests that long-term exposure to wildfire smoke may increase the risk of several cancers. Studies have reported possible associations with lung cancer, breast cancer, colorectal cancer, bladder cancer, and certain blood cancers
Although researchers say more studies are needed to establish a direct cause-and-effect relationship, the findings highlight the importance of limiting repeated smoke exposure.
Also read: How Air Pollution Puts Heart Patients At Risk - What You Can Do About It
Pregnant women are among the groups considered most vulnerable to wildfire smoke. Research suggests exposure during pregnancy may increase the risk of preterm birth, low birth weight and other pregnancy complications.
Healthcare providers recommend minimizing outdoor exposure whenever air quality deteriorates.
Even after visible smoke disappears, harmful particles may remain in the air. Experts recommend:
Credit: AI
When we think of dialysis, we often picture a machine filtering blood and keeping patients alive. What rarely comes to mind is the small blood vessel in the arm that makes the entire process possible.
For every patient on haemodialysis, the arteriovenous (AV) fistula is quite literally a lifeline. Without it, dialysis cannot be performed effectively. Yet, despite being one of the most important parts of treatment, fistula care remains one of the least understood aspects of kidney disease.
This silent gap in awareness is costing patients their lifeline.
India adds nearly 2.2 lakh new patients with end-stage kidney disease every year, creating a demand for over 3.4 crore dialysis sessions annually.
One of the biggest challenges we see in clinical practice is that patients often seek medical help only after the fistula has already stopped functioning.
The warning signs are usually ignored.
The vibration over the fistula becomes weaker. The arm begins to swell. Bleeding continues longer than usual after dialysis. Needle insertion becomes increasingly difficult. Sometimes dialysis itself becomes less effective.
By the time patients reach an interventional radiologist or vascular specialist, the fistula may already have developed significant narrowing (stenosis) or complete blockage.
Unfortunately, many of these complications are preventable if detected early.
In our experience, nearly 30% of patients eventually lose their fistula because they report too late, when timely intervention could have salvaged access.
Also read: COVID Spikes In India: Experts Allay Fears, Stress Vaccination And Masks
Unlike diabetes or blood pressure, there is no widespread public awareness around fistula surveillance.
Many dialysis patients receive instructions on medicines and dialysis schedules but very little education on how to examine their fistula every day.
There is also no universally implemented patient education protocol across dialysis centres, leading to inconsistent awareness about fistula care.
The result is simple: patients unknowingly damage the very access that keeps them alive.
Patients should examine their fistula daily.
A healthy fistula has a continuous buzzing sensation or “thrill.” If this vibration becomes weak or disappears, medical attention should be sought immediately.
Similarly, swelling of the arm, redness, prolonged bleeding after dialysis, pain around the fistula, or difficulty during needle insertion should never be dismissed as routine.
These are early warning signs - not inconveniences.
Also read: Omicron Sub-Lineages Likely Behind COVID Surge In India: Why Deaths Are Occurring
These small daily habits can often extend the life of a fistula by years.
One of the greatest advances in dialysis access care is that many fistula problems no longer require open surgery.
If narrowing is detected early, minimally invasive image-guided procedures such as fistuloplasty (balloon angioplasty) can restore blood flow, preserve the existing fistula and help patients continue dialysis without interruption.
The key, however, is timing.
A fistula that is evaluated early is often salvageable.
A fistula ignored for weeks may not be.
Every successful fistula represents months of planning, surgery and healing. Losing it means additional procedures, temporary catheters, higher infection risk, increased costs and emotional distress for patients already living with chronic kidney disease.
As doctors, we have become increasingly skilled at creating dialysis access.
The next challenge is ensuring patients know how to protect it.
Because for someone living with kidney failure, the fistula is not just another blood vessel.
It is the lifeline that keeps life moving.
By Dr. Avik Bhattacharyya, Senior Consultant - Interventional Radiology, CK Birla Hospitals, CMRI
Credit: iStock
GLP-1 drugs such as Ozempic, Wegovy, Mounjaro and liraglutide, best known for regulating appetite and aiding weight loss, may also help reduce symptoms of binge eating disorder (BED), which affects more than 17 million people worldwide, according to a new study.
The systematic review and meta-analysis, published in the journal eClinicalMedicine, found that GLP-1 drugs, with semaglutide as its key ingredient, reduced binge eating episodes, loss-of-control eating and emotional eating, highlighting their potential role in treating binge eating disorder alongside obesity.
Binge eating disorder affects over 17 million people globally, and around two-thirds of people with the condition also live with overweight or obesity. It is also common among individuals seeking weight-loss treatment.
"Binge eating disorder, where people regularly eat an excessive amount of food while feeling they have lost control, is common and highly impairing, affecting over 17 million people worldwide," said lead author Dr Ilaria Costantini from the Psychiatry Department at University College London (UCL), UK.
"But treatment options are limited and there are currently no approved medications, so there remains a need for better ways to help people living with this condition. We found evidence that weight loss drugs may help to manage some key symptoms of binge eating disorder," Costantini added.
Also read: Babies Without Vitamin K Shot At Higher Risk Of Brain Bleeding: Study
The researchers analyzed 25 randomized controlled trials conducted across 12 countries on four continents, involving 8,069 participants.
The trials evaluated GLP-1 drugs that target the appetite-regulating hormone GLP-1, including semaglutide (marketed as Ozempic or Wegovy), tirzepatide (Mounjaro) and liraglutide.
These medications suppress appetite by acting on the central nervous system and insulin secretion, delay stomach emptying, and may also influence brain pathways involved in reward and impulse control.
Compared with placebo or other treatments, people taking GLP-1 drugs reported:
Read More: Obesity-Driven CKM Syndrome A Growing Public Health Threat, Warns American Heart Association
The researchers also found that participants taking GLP-1 drugs reported greater cognitive or dietary restraint, meaning they made more deliberate efforts to limit what they ate.
The benefits extended beyond weight loss, with improvements seen in several behaviors associated with binge eating disorder.
While increased dietary restraint was observed, the researchers cautioned that it remains unclear whether this represents healthy self-regulation or a more rigid, potentially harmful eating pattern that could worsen binge eating over time.
"From the evidence available, we cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating. We hope that future research can clarify whether or not taking weight loss drugs might contribute to more pathological forms of eating restriction such as meal skipping," said Izzy Emptage from UCL Psychiatry.
The researchers said GLP-1 drugs could become an important addition to treatment plans for binge eating disorder when used alongside psychological therapies and social support.
However, they also highlighted important limitations. Most of the studies included in the review had a high risk of bias, were funded by pharmaceutical companies, and rarely included participants with a clinical diagnosis of binge eating disorder, reducing the certainty of the findings.
"GLP-1s may offer a promising additional treatment option for people living with both binge eating and obesity," the researchers said, while stressing that these drugs "should not be viewed as a standalone solution to binge eating disorder."
They added that larger, independently funded clinical trials are needed before these medications can be routinely recommended for treating binge eating disorders.
© 2024 Bennett, Coleman & Company Limited